Rabbit Recombinant Monoclonal ENO1 antibody - conjugated to Alexa Fluor® 594.
IgG
Rabbit
Alexa Fluor® 594
Ex: 590nm, Em: 617nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Liquid
Monoclonal
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Glycolytic enzyme the catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate (PubMed:29775581, PubMed:1369209). In addition to glycolysis, involved in various processes such as growth control, hypoxia tolerance and allergic responses (PubMed:2005901, PubMed:10802057, PubMed:12666133, PubMed:29775581). May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons (PubMed:12666133). Stimulates immunoglobulin production (PubMed:1369209).MBP1 binds to the myc promoter and acts as a transcriptional repressor. May be a tumor suppressor.
Alpha-enolase, 2-phospho-D-glycerate hydro-lyase, C-myc promoter-binding protein, Enolase 1, MBP-1, MPB-1, Non-neural enolase, Phosphopyruvate hydratase, Plasminogen-binding protein, NNE, ENO1, ENO1L1, MBPB1, MPB1
Rabbit Recombinant Monoclonal ENO1 antibody - conjugated to Alexa Fluor® 594.
Alpha-enolase, 2-phospho-D-glycerate hydro-lyase, C-myc promoter-binding protein, Enolase 1, MBP-1, MPB-1, Non-neural enolase, Phosphopyruvate hydratase, Plasminogen-binding protein, NNE, ENO1, ENO1L1, MBPB1, MPB1
IgG
Rabbit
Alexa Fluor® 594
Ex: 590nm, Em: 617nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Liquid
Monoclonal
EPR19758
Affinity purification Protein A
ab227978 does not cross-react with ENO2 or ENO3.
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Enolase 1 or alpha-enolase is an important enzyme in the glycolytic pathway. It catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate. We also refer to it as an enolase reaction. ENO1 protein has a molecular mass of approximately 47 kDa and is expressed in most tissues but found most abundantly in the brain muscle and liver. Additionally ENO1 can exist in both cytosolic and plasma membrane-associated forms playing functional roles in different cellular contexts.
The ENO1 protein serves multiple functions beyond its glycolytic activity. It also acts as a plasminogen receptor on the cell surface aiding in the modulation of pericellular and extracellular matrix degradation processes. Through this role ENO1 influences cell migration and tissue remodeling. This protein can form part of larger protein complexes contributing to its versatility in various cellular functions.
ENO1 plays a critical role in glycolysis a central metabolic pathway that converts glucose into pyruvate generating ATP as a result. In this pathway ENO1 closely interacts with other enzymes like phosphoglycerate kinase and pyruvate kinase. Additionally as a plasminogen receptor ENO1 links to the plasminogen activation pathway affecting fibrinolysis and cellular response to tissue injury.
ENO1 is associated with cancer and neurodegenerative diseases. Overexpression or aberrant regulation of ENO1 often correlates with tumor progression and metastasis in cancers such as lung and breast cancer. In neurodegenerative disorders like Alzheimer's disease abnormal functioning of ENO1 can impact brain energy metabolism and neuron degeneration. ENO1's interaction with other proteins such as beta-enolase further connects it to these conditions influencing disease mechanisms and patient outcomes.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com